A comparative analysis of HIV-specific mucosal/systemic T cell immunity and avidity following rDNA/rFPV and poxvirus-poxvirus prime boost immunisations

Vaccine

Volumn 29, Issue 16, 2011, Pages 3008-3020

  Ranasinghe, Charani ^a   Eyers, Fiona ^b   Stambas, John ^c,d,f   Boyle, David B ^d   Ramshaw, Ian A ^a   Ramsay, Alistair J ^e  

^a Australian National University   (Australia)

^b UNIVERSITY OF NEWCASTLE   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d CSIRO   (Australia)

^e LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f DEAKIN UNIVERSITY   (Australia)

Author keywords

DNA vaccines; Mucosal immunity; Poxvirus vectors; T cell avidity

Indexed keywords

DNA VACCINE; FOWLPOX VIRUS VECTOR; GAG PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS 1 VECTOR; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; LIPOFECTAMINE; PLASMID DNA; RECOMBINANT DNA; UNCLASSIFIED DRUG; VACCINIA VIRUS VECTOR; VIRUS DNA; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS; HUMORAL IMMUNITY; IMMUNIZATION; INFLUENZA; MOUSE; NONHUMAN; POXVIRUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; VAGINA SECRETION; VIRUS RECOMBINANT; WEIGHT REDUCTION;

ADMINISTRATION, INTRANASAL; AIDS VACCINES; ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; FOWLPOX VIRUS; HIV ANTIBODIES; HIV CORE PROTEIN P24; HIV INFECTIONS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNITY, MUCOSAL; IMMUNIZATION, SECONDARY; INJECTIONS, INTRAMUSCULAR; INTERFERON-GAMMA; INTERLEUKIN-2; MICE; MICE, INBRED BALB C; PLASMIDS; VACCINES, DNA;

EID: 79953166393     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.01.106     Document Type: Article

References (54)

1. Kelleher A.D., Puls R.L., Bebbington M., Boyle D., Ffrench R., Kent S.J., et al. A randomised, placebo-controlled phase I trial of DNA prime, recombinant fowlpox virus boost prophylactic vaccine for HIV-1. AIDS 2006, 20(2):294-297.
2. Sekaly R.P. The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development?. J Exp Med 2008, 205(1):7-12.
3. Kaul R., Plummer F.A., Kimani J., Dong T., Kiama P., Rostron T., et al. HIV-1-specific mucosal CD8+ lymphocyte responses in the cervix of HIV-1-resistant prostitutes in Nairobi. J Immunol 2000, 164:1602-1611.
4. Kozlowski P.A., Neutra M.R. The role of mucosal immunity in prevention of HIV transmission. Curr Mol Med 2003, 3(3):217-228.
5. Stevceva L., Strober W. Mucosal HIV vaccines: where are we now?. Curr HIV Res 2004, 2(1):1-10.
6. Belyakov I.M., Ahlers J.D., Berzofsky J.A. Mucosal AIDS vaccines: current status and future directions. Expert Rev Vaccines 2004, 3(4 Suppl.):S65-73.
7. Veazey R.S., DeMaria M., Chalifoux L.V., Shvetz D.E., Pauley D.R., Knight H.L., et al. Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection. Science 1998, 280(5362):427-431.
8. Ogra P.L., Faden H., Welliver R.C. Vaccination strategies for mucosal immune responses. Clin Microbiol Rev 2001, 14(2):430-445.
9. Somogyi P., Frazier J., Skinner M.A. Fowlpox virus host range restriction: gene expression. DNA replication, and morphogenesis in nonpermissive mammalian cells. Virology 1993, 197(1):439-444.
10. Leong KH, Ramsay AJ, Morin MJ, Robinson HL, Boyle DB, Ramshaw IA. Molecular approaches to the control of infectious diseases. Vaccine 95 1995;Brown F, Chanock H, Norrby E, Eds.:327-31.
11. Kent S.J., Zhao A., Best S.J., Chandler J.D., Boyle D.B., Ramshaw I.A. Enhanced T-cell immunogenicity and protective efficacy of a human immunodeficiency virus type 1 vaccine regimen consisting of consecutive priming with DNA and boosting with recombinant fowlpox virus. J Virol 1998, 72(12):10180-10188.
12. Boyle D.B., Anderson M.A., Amos R., Voysey R., Coupar B.E. Construction of recombinant fowlpox viruses carrying multiple vaccine antigens and immunomodulatory molecules. Biotechniques 2004, 37(1):104-106. 8-11.
13. Barnett S.W., Rajasekar S., Legg H., Doe B., Fuller D.H., Haynes J.R., et al. Vaccination with HIV-1 gp120 DNA induces immune responses that are boosted by a recombinant gp120 protein subunit. Vaccine 1997, 15(8):869-873.
14. Caver T.E., Lockey T.D., Srinivas R.V., Webster R.G., Hurwitz J.L. A novel vaccine regimen utilizing DNA, vaccinia virus and protein immunizations for HIV-1 envelope presentation. Vaccine 1999, 17(11-12):1567-1572.
15. Otten G., Schaefer M., Greer C., Calderon-Cacia M., Coit D., Kazzaz J., et al. Induction of broad and potent anti-human immunodeficiency virus immune responses in rhesus macaques by priming with a DNA vaccine and boosting with protein-adsorbed polylactide coglycolide microparticles. J Virol 2003, 77(10):6087-6092.
16. Epstein J.E., Charoenvit Y., Kester K.E., Wang R., Newcomer R., Fitzpatrick S., et al. Safety, tolerability, and antibody responses in humans after sequential immunization with a PfCSP DNA vaccine followed by the recombinant protein vaccine RTS,S/AS02A. Vaccine 2004, 22(13-14):1592-1603.
17. Stambas J., Brown S.A., Gutierrez A., Sealy R., Yue W., Jones B., et al. Long lived multi-isotype anti-HIV antibody responses following a prime-double boost immunization strategy. Vaccine 2005, 23(19):2454-2464.
18. Dale C.J., De Rose R., Wilson K.M., Croom H.A., Thomson S., Coupar B.E., et al. Evaluation in macaques of HIV-1 DNA vaccines containing primate CpG motifs and fowlpoxvirus vaccines co-expressing IFNgamma or IL-12. Vaccine 2004, 23(2):188-197.
19. Mwau M., Cebere I., Sutton J., Chikoti P., Winstone N., Wee E.G., et al. A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans. J Gen Virol 2004, 85(Pt 4):911-919.
20. Guimaraes-Walker A., Mackie N., McCormack S., Hanke T., Schmidt C., Gilmour J., et al. Lessons from IAVI-006, a phase I clinical trial to evaluate the safety and immunogenicity of the pTHr.HIVA DNA and MVA.HIVA vaccines in a prime-boost strategy to induce HIV-1 specific T-cell responses in healthy volunteers. Vaccine 2008, 26(51):6671-6677.
21. McCormack S., Stohr W., Barber T., Bart P.A., Harari A., Moog C., et al. EV02: a phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-NYVAC-C boost to NYVAC-C alone. Vaccine 2008, 26(25):3162-3174.
22. Alexander-Miller M.A., Leggatt G.R., Sarin A., Berzofsky J.A. Role of antigen CD8, and cytotoxic T lymphocyte (CTL) avidity in high dose antigen induction of apoptosis of effector CTL. J Exp Med 1996, 184(2):485-492.
23. La Gruta N.L., Turner S.J., Doherty P.C. Hierarchies in cytokine expression profiles for acute and resolving influenza virus-specific CD8+ T cell responses: correlation of cytokine profile and TCR avidity. J Immunol 2004, 172(9):5553-5560.
24. Kent S.J., Dale C.J., Ranasinghe C., Stratov I., De Rose R., Chea S., et al. Mucosally-administered human-simian immunodeficiency virus DNA and fowlpoxvirus-based recombinant vaccines reduce acute phase viral replication in macaques following vaginal challenge with CCR5-tropic SHIV(SF162P3). Vaccine 2005, 23:5009-5021.
25. Ranasinghe C., Medveczky J.C., Woltring D., Gao K., Thomson S., Coupar B.E.H., et al. Evaluation of fowlpox-vaccinia virus prime-boost vaccine strategies for high-level mucosal and systemic Iimmunity against HIV-1. Vaccine 2006, 24:5881-5895.
26. Ranasinghe C., Turner S.J., McArthur C., Sutherland D.B., Kim J.H., Doherty P.C., et al. Mucosal HIV-1 pox virus prime-boost immunization induces high-avidity CD8+ T cells with regime-dependent cytokine/granzyme B profiles. J Immunol 2007, 178(4):2370-2379.
27. Boyle D.B., Coupar B.E., Both G.W. Multiple-cloning-site plasmids for the rapid construction of recombinant poxviruses. Gene 1985, 35:169-177.
28. Coupar B.E.H., Purcell D.F.J., Thomson S.A., Ramshaw I.A., Kent S.J., Boyle D.B. Fowlpox virus vaccines for HIV and SIV clinical and pre-clinical trials. Vaccine 2006, 24(9):1378-1388.
29. Cukalac T., Moffat J.M., Venturi V., Davenport M.P., Doherty P.C., Turner S.J., et al. Narrowed TCR diversity for immunised mice challenged with recombinant influenza A-HIV Env(311-320) virus. Vaccine 2009, 27(48):6755-6761.
30. Sexton A., De Rose R., Reece J.C., Alcantara S., Loh L., Moffat J.M., et al. Evaluation of recombinant influenza virus-simian immunodeficiency virus vaccines in macaques. J Virol 2009, 83(15):7619-7628.
31. Ranasinghe C., Ramshaw I.A. Immunisation route-dependent expression of IL-4/IL-13 can modulate HIV-specific CD8(+) CTL avidity. Eur J Immunol 2009, 39(7):1819-1830.
32. De Rose R., Sullivan M.T., Dale C.J., Kelleher A.D., Emery S., Cooper D.A., et al. Dose-response relationship of DNA and recombinant fowlpox virus prime-boost HIV vaccines: implications for future trials. Hum Vaccine 2006, 2(3):134-136.
33. Amara R.R., Villinger F., Altman J.D., Lydy S.L., O'Neil S.P., Staprans S.I., et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 2001, 292(5514):69-74.
34. Horton H., Vogel T.U., Carter D.K., Vielhuber K., Fuller D.H., Shipley T., et al. Immunization of rhesus macaques with a DNA prime/modified vaccinia virus Ankara boost regimen induces broad simian immunodeficiency virus (SIV)-specific T-cell responses and reduces initial viral replication but does not prevent disease progression following challenge with pathogenic SIVmac239. J Virol 2002, 76(14):7187-7202.
35. Casimiro D.R., Wang F., Schleif W.A., Liang X., Zhang Z.Q., Tobery T.W., et al. Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with dna and recombinant adenoviral vaccine vectors expressing Gag. J Virol 2005, 79(24):15547-15555.
36. De Rose R., Batten C.J., Smith M.Z., Fernandez C.S., Peut V., Thomson S., et al. Comparative efficacy of subtype AE simian-human immunodeficiency virus priming and boosting vaccines in pigtail macaques. J Virol 2007, 81(1):292-300.
37. Imaoka K., Miller C.J., Kubota M., McChesney M.B., Lohman B., Yamamoto M., et al. Nasal immunisation of nonhuman primates with simian immunodeficiency virus p55gag and cholera toxin adjuvant induces Th1/Th2 help for virus-specific immune responses in reproductive tissues. J Immunol 1998, 161:5952-5958.
38. Hagiwara Y., Kawamura Y.I., Kataoka K., Rahima B., Jackson R.J., Komase K., et al. A second generation of double mutant cholera toxin adjuvants: enhanced immunity without intracellular trafficking. J Immunol 2006, 177(5):3045-3054.
39. Gherardi M.M., Esteban M. Recombinant poxviruses and mucosal vaccine vectors. J Gen Virol 2005, 86:2925-2936.
40. Belyakov I.M., Ahlers J.D., Nabel G.J., Moss B., Berzofsky J.A. Generation of functionally active HIV-1 specific CD8+ CTL in intestinal mucosa following mucosal, systemic or mixed prime-boost immunization. Virology 2008, 381(1):106-115.
41. Ramirez J.C., Finke D., Esteban M., Kraehenbuhl J.P., Acha-Orbea H. Tissue distribution of the Ankara strain of vaccinia virus (MVA) after mucosal or systemic administration. Arch Virol 2003, 148(5):827-839.
42. Huang X., Liu L., Ren L., Qiu C., Wan Y., Xu J. Mucosal priming with replicative Tiantan vaccinia and systemic boosting with DNA vaccine raised strong mucosal and systemic HIV-specific immune responses. Vaccine 2007, 25(52):8874-8884.
43. Corbett M., Bogers W.M., Heeney J.L., Gerber S., Genin C., Didierlaurent A., et al. Aerosol immunization with NYVAC and MVA vectored vaccines is safe, simple, and immunogenic. Proc Natl Acad Sci USA 2008, 105(6):2046-2051.
44. Belyakov I.M., Ahlers J.D. Comment on " trafficking of antigen-specific CD8+ T lymphocytes to mucosal surfaces following intramuscular vaccination" J Immunol 2009, 182(4):1779. [author reply -80].
45. Lehner T., Wang Y., Cranage M., Bergmeier L.A., Mitchell E., Tao L., et al. Protective mucosal immunity elicited by targeted iliac lymph node immunization with a subunit SIV envelope and core vaccine in macaques. Nat Med 1996, 2(7):767-775.
46. Ito K., Shinohara N., Kato S. DNA immunization via intramuscular and intradermal routes using a gene gun provides different magnitudes and durations on immune response. Mol Immunol 2003, 39(14):847-854.
47. Alexander-Miller M.A. High-avidity CD8+ T cells: optimal soldiers in the war against viruses and tumors. Immunol Res 2005, 31(1):13-24.
48. Belyakov I.M., Kuznetsov V.A., Kelsall B., Klinman D., Moniuszko M., Lemon M., et al. Impact of vaccine-induced mucosal high-avidity CD8+ CTLs in delay of AIDS viral dissemination from mucosa. Blood 2006, 107(8):3258-3264.
49. Kroger C.J., Alexander-Miller M.A. Cutting edge: CD8+ T cell clones possess the potential to differentiate into both high- and low-avidity effector cells. J Immunol 2007, 179(2):748-751.
50. Duvall M.G., Jaye A., Dong T., Brenchley J.M., Alabi A.S., Jeffries D.J., et al. Maintenance of HIV-specific CD4+ T cell help distinguishes HIV-2 from HIV-1 infection. J Immunol 2006, 176(11):6973-6981.
51. Aagaard C.S., Hoang T.T., Vingsbo-Lundberg C., Dietrich J., Andersen P. Quality and vaccine efficacy of CD4+ T cell responses directed to dominant and subdominant epitopes in ESAT-6 from Mycobacterium tuberculosis. J Immunol 2009, 183(4):2659-2668.
52. Ahmed N., Gottschalk S. How to design effective vaccines: lessons from an old success story. Expert Rev Vaccines 2009, 8(5):543-546.
53. Ferre A.L., Hunt P.W., Critchfield J.W., Young D.H., Morris M.M., Garcia J.C., et al. Mucosal immune responses to HIV-1 in elite controllers: a potential correlate of immune control. Blood 2009, 113(17):3978-3989.
54. Harari A., Cellerai C., Enders F.B., Kostler J., Codarri L., Tapia G., et al. Skewed association of polyfunctional antigen-specific CD8 T cell populations with HLA-B genotype. Proc Natl Acad Sci USA 2007, 104(41):16233-16238.